Abstract
We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
MeSH terms
-
Antigens, Surface / metabolism*
-
Carcinoma, Neuroendocrine / metabolism
-
Carcinoma, Neuroendocrine / pathology*
-
Carcinoma, Neuroendocrine / radiotherapy*
-
Glutamate Carboxypeptidase II / metabolism*
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Octreotide / analogs & derivatives*
-
Octreotide / therapeutic use
-
Organometallic Compounds / therapeutic use*
-
Prostatic Neoplasms, Castration-Resistant / metabolism
-
Prostatic Neoplasms, Castration-Resistant / pathology*
-
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
-
Receptors, Somatostatin / metabolism
Substances
-
Antigens, Surface
-
Organometallic Compounds
-
Receptors, Somatostatin
-
lutetium Lu 177 dotatate
-
FOLH1 protein, human
-
Glutamate Carboxypeptidase II
-
Octreotide